Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is planning to meet with the US Food and Drug Administration early next year in anticipation of moving its wet age-related macular degeneration (AMD) drug candidate CLS-AX

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lenz/Graphite Combination Is All-Stock

The biopharmaceutical industry showed in multiple ways during the second week of August how a rising tide lifts all ships. Signs that the US may be able to avoid a recession – low unemployment rates a

There are five novel agents with October 2021 goal dates on the FDA’s user fee calendar, but at least one – Omeros Corporation ’s narsoplimab – already appears unlikely to see a decision, let alone a